

**TABLE 1: BASELINE CHARACTERISTICS OF THE PATIENTS ACCORDING TO EXTENT OF PREVIOUS EXPOSURE TO ANTI RETRO VIRAL AGENTS**

CHARACTERISTIC	ALL PATIENTS		NO PRIOR EXPOSURE		PRIOR EXPOSURE	
	N	%	N	%	N	%
MALE SEX	2029	82.3%	892	83.6%	1137	81.2%
AGE YEARS - MEAN SD	34.9	8.7	34.0	8.4	35.6	8.8
RACE OR ETHNIC GROUP						
WHITE, NON HISPANIC	1730	70.1%	707	66.3%	1023	73.1%
BLACK, NON HISPANIC	409	16.6%	214	20.1%	195	13.9%
HISPANIC	291	11.8%	131	12.3%	160	11.4%
OTHER	37	1.5%	15	1.4%	22	1.6%
RISK FACTORS						
HOMOSEXUALITY	1608	65.3%	719	67.5%	889	63.7%
INJECTION - DRUG USE	335	14.4%	154	14.5%	201	14.4%
HEMOPHILIA	202	8.2%	44	4.1%	158	11.3%
KARNOFSKY SCORE OF 100	1448	58.8%	657	61.7%	791	56.5%
SYMPTOMATIC HIV INFECTION	438	17.8%	170	15.9%	268	19.1%
CD4 CELL COUNT - CELLS/MM <sup>3</sup>	352.5	107.5	372.1	110.2	337.6	102.9
MEDIAN LENGTH IN MONTHS OF PRIOR ANTI RETROVIRAL THERAPY (UPPER & LOWER QUARTILES)						